Efficacy of Entecavir in Chronic Hepatitis B Patients with Persistently Normal Alanine Aminotransferase: Randomized,Double-Blind,Placebo-Controlled Study

Abstract

Background

It is still inconclusive whether chronic hepatitis B (CHB) patients with persistently normal alanine aminotransferase (PNALT) should receive nucleoside/nucleotide analogues. This study is to evaluate the efficacy of entecavir in improving liver histology in CHB patients with PNALT.

Methods

In this prospective randomized, double-blind, placebo-controlled study, 380 CHB patients with PNALT were screened, 82 patients received biopsy and 43 patients met the HBV DNA and histology criteria and were randomly assigned to either an entecavir or placebo group for 52 weeks, with 22 and 21 in each group, respectively. The primary objective was to evaluate histological improvement. The secondary objective is to evaluate virological efficacy.

Results

A total of eight (38.1%) patients in the entecavir group and eight (44.4%) in the placebo group (P=0.752) showed histological improvement. The decrease in total Knodell scores (±sd) was 1.3 ±1.9 in the entecavir group and 1.5 ±2.2 in the placebo group (P=0.803). The subjects with undetectable HBV DNA at week 52 were 16/21 (76.2%) in the entecavir group and 0/18 (0%) in the placebo group (P<0.001). The mean HBV DNA reduction from baseline to week 52 was 4.73 ±0.83 in the entecavir and 0.25 ±0.81 in the placebo group (P<0.001).

Conclusions

CHB patients with PNALT receiving entecavir therapy for one year achieved virological efficacy, but not histological benefit. ClinicalTrials.gov number NCT01833611.

References

Lok

A.S.

The maze of treatments for hepatitis B. N Engl J Med 2005; 352: 2743–2746.

Lavanchy

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97–107.

Liaw

Y.F.

HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; 3: 425–433.

Carman

W.F.

, Jacyna

M.R.

, Hadziyannis

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588–591.

Lok

A.S.

, Akarca

, Greene

Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91: 4077–4081.

Hadziyannis

S.J.

, Vassilopoulos

Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617–624.

Chen

C.H.

, Lee

C.M.

, Lu

S.N.

Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol 2005; 43: 6000–6006.

Lin

C.L.

, Liao

L.Y.

, Liu

C.J.

Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. J Gastroenterol 2002; 37: 283–287.

Chen

C.J.

, Yang

H.I.

, Su

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.

10.

Iloeje

U.H.

, Yang

H.I.

, Su

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–686.

11.

Keeffe

E.B.

, Dieterich

D.T.

, Han

S.H.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315–1341.

12.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B. Hepatology 2007; 45: 507–539.

13.

Liaw

Y.F.

, Leung

, Kao

J.H.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263–283.

14.

European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.

15.

Kumar

, Sarin

S.K.

, Hissar

Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376–1384.

16.

Lai

, Hyatt

B.J.

, Nasser

, Curry

, Afdhal

N.H.

The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760–767.

17.

Lin

C.L.

, Liao

L.Y.

, Liu

C.J.

Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007; 45: 1193–1198.

18.

Ikeda

, Arase

, Saitoh

Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. Am J Med 2006; 119: 977–985.

19.

Chu

C.M.

, Liaw

Y.F.

Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693–1699.

20.

Kumada

, Toyoda

, Kiriyama

Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol 2010; 82: 539–545.

21.

Innaimo

S.F.

, Seifer

, Bisacchi

G.S.

, Standring

D.N.

, Zahler

, Colonno

R.J.

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41: 1444–1448.

22.

Chang

T.T.

, Gish

R.G.

, de Man

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–1010.

23.

Lai

C.L.

, Shouval

, Lok

A.S.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011–1020.

24.

Chang

T.T.

, Liaw

Y.F.

, Wu

S.S.

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886–893.

25.

Liu

W.C.

, Mizokami

, Buti

Simultaneous quantification and genotyping of hepatitis B virus for genotypes A to G by real-time PCR and two-step melting curve analysis. J Clin Microbiol 2006; 44: 4491–4497.

26.

Knodell

R.G.

, Ishak

K.G.

, Black

W.C.

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435.

27.

Marcellin

, Gane

, Buti

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468–475.

28.

Brunt

E.M.

, Kleiner

D.E.

, Wilson

L.A.

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810–820.

29.

Lai

C.L.

, Chien

R.N.

, Leung

N.W.

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61–68.

30.

Marcellin

, Chang

T.T.

, Lim

S.G.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808–816.

31.

Papatheodoridis

G.V.

, Manolakopoulos

, Liaw

Y.F.

, Lok

Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012; 57: 196–202.

32.

Martinot-Peignoux

, Boyer

, Colombat

Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002; 36: 543–546.

33.

Papatheodoridis

G.V.

, Manesis

E.K.

, Manolakopoulos

Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?

Hepatology 2008; 48: 1451–1459.

34.

Zacharakis

, Koskinas

, Kotsiou

The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol 2008; 49: 884–891.

35.

Scaglione

S.J.

, Lok

A.S.

Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012; 142: 1360–1368.e1.